uniQure (QURE) Total Liabilities (2015 - 2026)
uniQure (QURE) posted quarterly Total Liabilities of $661.1 million for Q2 2026, up 12.25% year-over-year from $588.9 million in Q2 2025, and up 5.04% quarter-over-quarter from $629.4 million in Q1 2026.
Analysis
uniQure (QURE) Total Liabilities (2015 - 2026) Analysis & Trends
uniQure's Total Liabilities history runs 12 years deep, the most recent figure standing at $661.1 million for Q2 2026.
- In Q2 2026, Total Liabilities rose 12.25% year-over-year to $661.1 million; the TTM figure through Jun 2026 stood at $661.1 million (up 12.25% YoY), while the FY2025 annual figure was $626.0 million, up 11.13% from the prior year.
- Total Liabilities for Q2 2026 stood at $661.1 million, up from $629.4 million in the prior quarter.
- The five-year high for Total Liabilities was $661.1 million in Q2 2026, with the low at $211.1 million in Q1 2022.
- The 5-year median for Total Liabilities is $589.7 million (2023), against an average of $503.0 million.
- Peak annual rise in Total Liabilities reached 185.61% in 2024, while the deepest fall reached 9.73% in 2024.
- uniQure's Total Liabilities stood at $229.0 million in 2022, then jumped by 172.55% to $624.0 million in 2023, then retreated by 9.73% to $563.3 million in 2024, then advanced by 11.13% to $626.0 million in 2025, then grew by 5.6% to $661.1 million in 2026.
- Business Quant data shows QURE's Total Liabilities at $661.1 million in Q2 2026, $629.4 million in Q1 2026, and $626.0 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 4.20 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 1.72 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 4.00 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 10.03 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.35 Bn |
| 10 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn | 661.05 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 661.05 Mn |
| Mar 31, 2026 | 629.36 Mn |
| Dec 31, 2025 | 626.01 Mn |
| Sep 30, 2025 | 659.64 Mn |
| Jun 30, 2025 | 588.89 Mn |
| Mar 31, 2025 | 571.72 Mn |
| Dec 31, 2024 | 563.29 Mn |
| Sep 30, 2024 | 589.99 Mn |
| Jun 30, 2024 | 633.74 Mn |
| Mar 31, 2024 | 623.30 Mn |
| Dec 31, 2023 | 624.02 Mn |
| Sep 30, 2023 | 602.77 Mn |
| Jun 30, 2023 | 589.45 Mn |
| Mar 31, 2023 | 218.23 Mn |
| Dec 31, 2022 | 228.96 Mn |
| Sep 30, 2022 | 217.06 Mn |
| Jun 30, 2022 | 214.72 Mn |
| Mar 31, 2022 | 211.15 Mn |
| Dec 31, 2021 | 213.40 Mn |
| Sep 30, 2021 | 183.87 Mn |